Last synced on 18 April 2025 at 11:05 pm

Magnetic Cell Selection System For Cd34+ Cells From Hpc-Apheresis Used In Treatment Of Acute Myeloid Leukemia (Aml)

Page Type
Product Code
Definition
For processing hematopoietic progenitor cells-apheresis (HPC-A) from an HLA-identical donor to obtain a CD34 positive cell enriched population that will provide for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft-vs-host disease (GVHD) prophylaxis.
Physical State
Anti-CD34 Antibody, Paramagnetic dextran beads, Tubing, Permanent Magnet, Software controlled pumps and valves, Buffers, Filters, Polymer Bags
Technical Method
To select CD34+ hematopoietic progenitor cells from apheresis (HPC-A) labeled with antibody conjugated to paramagnetic beads using a semiautomated magnetic column.
Target Area
Hematopoietic Progenitor Cells-apheresis (HPC-A) separated from whole blood.
Review Panel
Hematology
Submission Type
HDE - Humanitarian Device Exemption
Device Classification
F
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
Yes
Life-Sustain/Support Device
Yes
Third Party Review
Not Third Party Eligible

No Linked CFR Text

The FDA has not linked product code OVG to any particular section of the CFR (Code of Federal Regulations). There are multiple reasons why this might be the case:

  • The product code was created for a class III submission that does not follow the normal PMN or PMA path - e.g., for a device that falls under HDE (Humanitarian Device Exemption) or EUA (Emergency Use Authorization).
  • The FDA has generated the product code for an existing Class III device, as a result of a PMA supplement that modifies the device in a way that it can't fit under the existing product code originally assigned
  • The product code was created for internal use at the FDA, and not for classification or regulatory-related purposes.

Magnetic Cell Selection System For Cd34+ Cells From Hpc-Apheresis Used In Treatment Of Acute Myeloid Leukemia (Aml)

Page Type
Product Code
Definition
For processing hematopoietic progenitor cells-apheresis (HPC-A) from an HLA-identical donor to obtain a CD34 positive cell enriched population that will provide for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft-vs-host disease (GVHD) prophylaxis.
Physical State
Anti-CD34 Antibody, Paramagnetic dextran beads, Tubing, Permanent Magnet, Software controlled pumps and valves, Buffers, Filters, Polymer Bags
Technical Method
To select CD34+ hematopoietic progenitor cells from apheresis (HPC-A) labeled with antibody conjugated to paramagnetic beads using a semiautomated magnetic column.
Target Area
Hematopoietic Progenitor Cells-apheresis (HPC-A) separated from whole blood.
Review Panel
Hematology
Submission Type
HDE - Humanitarian Device Exemption
Device Classification
F
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
Yes
Life-Sustain/Support Device
Yes
Third Party Review
Not Third Party Eligible

No Linked CFR Text

The FDA has not linked product code OVG to any particular section of the CFR (Code of Federal Regulations). There are multiple reasons why this might be the case:

  • The product code was created for a class III submission that does not follow the normal PMN or PMA path - e.g., for a device that falls under HDE (Humanitarian Device Exemption) or EUA (Emergency Use Authorization).
  • The FDA has generated the product code for an existing Class III device, as a result of a PMA supplement that modifies the device in a way that it can't fit under the existing product code originally assigned
  • The product code was created for internal use at the FDA, and not for classification or regulatory-related purposes.